Systemic capsaicin for burning mouth syndrome: short‐term results of a pilot study

Petruzzi, Massimo; Lauritano, D; Benedittis, M. De; Baldoni, M; Serpico, Rosario

doi:10.1111/j.1600-0714.2004.0194n.x

Cited by 117 publications

(127 citation statements)

References 15 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…The communication of different therapeutic measures to control the BMS is wide in the world literature (11)(12)(13)(14)(15)(16)(17)(18)(19)(20). The Gabapentin was used by White et al (15) in a case of a patient with BMS obtaining healing of the case and it was subsequently used by Heckmann et al (16) who conducted a study with gabapentin in 15 patients, where the initial dose was 300 mg / day and then grew at a rate of 300 mg every 48 hours to a maximum of 2400 mg / day.…”

Section: Discussionmentioning

confidence: 99%

Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: A randomized, double-blind, placebo controlled trial

López-D'alessandro¹,

Escovich²

2011

Med Oral

100

180

View full text Add to dashboard Cite

Burning Mouth Syndrome (BMS) is a disease that manifests as burning in the tongue or in any area of the oral mucosa, in the absence of clinically verifiable injuries. Objectives: To verify the efficacy of alpha lipoic acid (ALA) and gabapentin (GABA), used individually and jointly, to reduce the burning in patients with burning mouth and establish a drug therapy for the BMS. Study Design: During April and May 2008, we conducted a randomized, double-blind, placebo-controlled trial in the Department of Clinical Stomatology, Faculty of Dentistry, Rosario, Argentina. The gathering of patients was between those ones with BMS who were treated in our service between March 2003 and March 2008 without complying with the applied treatments. The 120 patients were randomly divided into 4 groups and were provided, by lot and in a blinded fashion, with four different treatment cycles consisting of the following drugs: Group A (n = 20) 600 mg / day of alpha lipoic acid for two months, Group B (n = 20) 300 mg / day of gabapentin for two months, Group C (n = 20) a combination of both drugs for two months and Group D (n = 60) 100 mg / day of cellulose starch for two months (control group). Results and Conclusions: All 120 patients completed the treatment. The best response was obtained with the combination of ALA + GABA, with a 70% of the cases with reduced burning in this group and a 13.2 times greater chance of presenting positive changes for these patients than those taking placebo. The combined use of drugs that act at different levels of the nociceptive system can be useful for the treatment of this syndrome.

show abstract

Section: Discussionmentioning

confidence: 99%

Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: A randomized, double-blind, placebo controlled trial

López-D'alessandro¹,

Escovich²

2011

Med Oral

100

180

View full text Add to dashboard Cite

show abstract

“…Systemic use of capsaicin (0.25% three times a day for one month) is found a significant reduction of pain intensity. It is not recommended for extended treatment as 32% of patients experience gastric pain after 4 weeks of treatment 54 . Systemic use of clonazepam (0.25 mg/day increasing to a maximum of 3 mg/day) has also been found better results.…”

Section: Treatmentmentioning

confidence: 99%

Burning Mouth Syndrome: A Review

Sadat

Chowdhury

Baten³

2017

J. Bangladesh Coll. Phys.

View full text Add to dashboard Cite

Burning Mouth Syndrome (BMS) is characterized by chronic oro-facial pain in the absence of specific oral lesions & clinically apparent mucosal alterations. It is more commonly observed in middle aged patients & postmenopausal women. It often affects tongue, cheek, lip, hard & soft palate. Usually symptoms are better observed in morning, worsen during the day and typically subside at night. The condition is multifactorial origin, often idiopathic and its etiopathogenesis remain largely enigmatic. Associated medical conditions may include neurologic and metabolic disorder, gastrointestinal, urogenital as well as drug reactions. BMS are of two types, primary & secondary. Primary BMS is essential or idiopathic where secondary BMS is caused by local, systemic and/or psychological factors. Clinical diagnosis depends on the careful history taking, physical examinations and laboratory findings. Vitamin, Zinc or Hormone replacement therapy has been found to be effective with deficiency of the corresponding factors. The drug therapy with alpha-lipoic acid, capsaicin, clonazepam, benzodiazepines, tricyclic antidepressants, anticonvulsants may be effective in symptomatic treatment of BMS. But the treatment is still unsatisfactory and there is no definitive cure.J Bangladesh Coll Phys Surg 2016; 34(3): 151-159

show abstract

“…Petruzzi et al 17 evaluated the effect of systemic capsaicin over four weeks. The authors observed a significant reduction of the symptom and suggested that the positive results support the hypothesis of neurologic etiology.…”

Section: Introductionmentioning

confidence: 99%

“…The authors observed a significant reduction of the symptom and suggested that the positive results support the hypothesis of neurologic etiology. However, the treatment caused gastric pain in 32% of the patients, with symptoms starting from the second week of treatment 17 . The use of topical capsaicin presents the unpleasant side effect because it is derived from pepper, but has a positive effect in reducing the symptoms 15 .…”

Section: Introductionmentioning

confidence: 99%

Clinical characteristics and therapeutic response in patients with Burning Mouth Syndrome: accompanying 2 years

Carvalho

Gallo

Sugaya

et al. 2017

Rev. odontol. UNESP

View full text Add to dashboard Cite

ResumoIntrodução: A Síndrome de Ardência Bucal (SAB) é uma condição caracterizada pelo sintoma de ardência na mucosa oral na ausência de qualquer sinal clínico. Sua etiologia ainda é desconhecida e, até o momento, não dispõe de tratamento efetivo. Objetivo: Avaliar o perfil do paciente portador de SAB, as terapias instituídas e seus resultados em estudo retrospectivo. Material e método: Foram coletados os dados clínicos e terapêuticos dos prontuários de pacientes diagnosticados com SAB, no período de janeiro de 2013 a abril de 2015, no Ambulatório da Disciplina de Estomatologia Clínica da Faculdade de Odontologia da Universidade de São Paulo. Os critérios para o diagnóstico utilizados se basearam nos estabelecidos pela International Headache Society em 2013 e foram observadas as terapêuticas empregadas e seus resultados. Resultado: Doze pacientes foram diagnosticadas com SAB neste período, todas do sexo feminino, média de idade 61,18 anos, e a principal região acometida pelo sintoma de ardor foi o ápice de língua. O tempo de duração deste sintoma variou de 6 meses a 25 anos. As terapias utilizadas para o controle de sintomas da SAB foram capsaicina, clonazepan tópico, laserterapia e homeopatia. Dentre as terapias instituídas, a capsaicina apresentou efeito imediato na redução dos sintomas. Conclusão: O presente estudo demonstrou que os desafios que circundam a obtenção de um tratamento efetivo para a SAB são diversos e estão principalmente relacionados ao desconhecimento da etiopatogenia da doença. O perfil demográfico dos pacientes aqui estudados foi semelhante ao descrito na literatura disponível, entretanto, as variáveis representadas por sintomas secundários (história médica, níveis de ansiedade e depressão) podem constituir fatores modificadores da resposta terapêutica e da própria etiopatogenia da doença. Descritores: Síndrome da Ardência Bucal; tratamento; dor neuropática AbstractIntroduction: Burning Mouth Syndrome (BMS) is a condition characterized by burning symptom of the oral mucosa in the absence of clinical signs. Its etiology is still unknown and, and to date there is no effective treatment. Purpose: The aim of this study was to evaluate patients with BMS profile and the therapies results in a retrospective study. Material and method: Clinical and therapeutic data were collected from records of patients with BMS diagnosed between January 2013 to April 2015 at the Clinic of Stomatology Clinic, Faculdade de Odontologia of Universidade de São Paulo, according to the criteria established by the International Headache Society in 2013. The therapies used for BMS control were also evaluated. Result: Twelve patients were diagnosed with BMS at this period. All of them were women with a mean age of 61.18 years and the apex of the tongue was the most common affected site and the duration of the burning sensation ranged from 6 months to 25 years. Many therapies were prescribed for BMS control, such as topical capsaicin, topical clonazepan, low level laser therapy and homeopathy. Among the established therapie...

show abstract

Systemic capsaicin for burning mouth syndrome: short‐term results of a pilot study

Cited by 117 publications

References 15 publications

Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: A randomized, double-blind, placebo controlled trial

Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: A randomized, double-blind, placebo controlled trial

Burning Mouth Syndrome: A Review

Clinical characteristics and therapeutic response in patients with Burning Mouth Syndrome: accompanying 2 years

Contact Info

Product

Resources

About